Goldman Sachs Removes 'Sell' Rating On OSI Pharmaceuticals (OSIP), Ups to Neutral
Tweet Send to a Friend
Goldman Sachs upgrades OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) from Sell to Neutral and raises their ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
